Cargando...
Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
Adolescents (12–17 years of age) with severe eosinophilic asthma experience frequent exacerbations and reduced lung function leading to poor health-related quality of life. Mepolizumab is approved for add-on maintenance therapy in patients with severe eosinophilic asthma ≥ 6 years of age in the EU a...
Guardado en:
| Publicado en: | Allergy Asthma Clin Immunol |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6724286/ https://ncbi.nlm.nih.gov/pubmed/31507641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13223-019-0366-x |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|